Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Phebra Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (101)
Cancellation by sponsor (24)
Section 14, TGO91 consent (16)
Australian Public Assessment Report (AusPAR) (5)
Prescription medicine registration (3)

Date

2024 (3)
2022 (2)
2021 (1)
2020 (19)
2019 (3)
2018 (3)
2017 (27)
2016 (2)
2015 (1)
2014 (4)
2013 (2)
2012 (3)
2011 (3)
2010 (6)
2009 (6)
2007 (3)
2005 (1)
2004 (2)
2003 (1)
2002 (3)
2001 (1)
2000 (1)
1997 (2)
1994 (5)
1993 (3)
1991 (42)

Results for "[search-keyword]"

Search

Sponsor content

149 result(s) found, displaying 41 to 50

Methadone Injection BP 10 mg in 1 mL Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Phebra Pty Ltd
COLISTIMIXIN PHEBRA colistimethate sodium 1million IU powder for nebuliser solution vial (211398)

2 April 2014

ARTG

Australian Register of Therapeutic Goods (ARTG) information for COLISTIMIXIN PHEBRA colistimethate sodium 1million IU powder for nebuliser solution vial.
DigiFab Digoxin-specific antibody fragment f(Ab) (ovine) 40mg powder for injection vial (203623)

14 February 2014

ARTG

Australian Register of Therapeutic Goods (ARTG) information for DigiFab Digoxin-specific antibody fragment f(Ab) (ovine) 40mg powder for injection vial.
Fluorescein Sodium Injection 10% Cancelled under s30(1)(c)

10 February 2017

Cancellation by sponsor

Requested by Phebra Pty Ltd
TOBRA-DAY 500mg/5mL Injection Cancelled under s30(1)(c)

10 February 2017

Cancellation by sponsor

Requested by Phebra Pty Ltd
CAFNEA INJECTION Cancelled under s30(1)(c)

10 February 2017

Cancellation by sponsor

Requested by Phebra Pty Ltd
CAFNEA Oral Solution Cancelled under s30(1)(c)

10 February 2017

Cancellation by sponsor

Requested by Phebra Pty Ltd
Paraldehyde Injection BP Cancelled under s30(1)(c)

10 February 2017

Cancellation by sponsor

Requested by Phebra Pty Ltd
Fluorescein Sodium Injection 10% Cancelled under s30(1)(c)

10 February 2017

Cancellation by sponsor

Requested by Phebra Pty Ltd
TOBRA-DAY 500mg/5mL Injection Cancelled under s30(1)(c)

10 February 2017

Cancellation by sponsor

Requested by Phebra Pty Ltd

Pages

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.